On June 22, 2017, the U.S. Food and Drug Administration granted (FDA) regular approvals to dabrafenib and trametinib (Taflinar® and Mekinist®, Novartis Pharmaceuticals Inc.) administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
On June 22, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to the combination of rituximab and hyaluronidase human (Rituxan Hycela, Genentech Inc.) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.
A combination of nivolumab and ipilimumab improved overall survival when compared to either drug alone, according to results from a recent study reported at the American Association for Cancer Research 2017 annual meeting.
Oncology clinicians can expect to continue to see new targeted and immunotherapy drugs emerge as clinically approved agents in the fight against cancer. Five cancer-related U.S. Food and Drug Administration (FDA) approvals occurred in the first quarter of 2017; following are their indications for treatment and associated clinical implications. You’ll recognize that some of the agents were already FDA approved for other uses, but as clinical trials continue and new data emerge, clinical use is expanding to other disease sites and indications.
In Washington, DC, the healthcare debate rages on. Currently, Republican senators are working behind closed doors to modify and change the House-passed American Health Care Act (AHCA). As it stands, the AHCA is the replacement plan for the Affordable Care Act (ACA), known to most Americans as Obamacare. While legislators continue to debate in Washington, the insurance marketplace carries on. United Healthcare recently announced its departure from the ACA’s marketplace exchange, another in list of insurance companies that have chosen to leave.
During a session at the Oncology Nurse Advisor Navigation Summit, ONS member Pamela J. Haylock, PhD, RN, FAAN, at the Association for Vascular Access in Medina, TX, and Cindy Stern, RN, MSN, CCRP, of the University of Pennsylvania Cancer Network, delivered a joint presentation about some of the hurdles nurse navigators face.
The 2012 American Cancer Society (ACS) guidelines on nutrition and physical activity for cancer survivors suggest achieving and maintaining a healthy weight, engaging in regular physical exercise and following healthy dietary patterns.
The cost of cancer has increased substantially over the years and is continuing to trend upward. During a session at the Oncology Nurse Advisor Navigation Summit, Yousuf Zafar, MD, MHS, an associate professor of medicine and public policy at Duke Cancer Institute, gave some facts and figures on cancer costs and how these are impacting patient well-being.
The triple aim of healthcare is patient satisfaction, quality outcomes, and decreased costs. Navigation is the key to effective care delivery, said Regina Cunningham, PhD, RN, NEA-BC, FAAN, chief executive officer of the Hospital of the University of Pennsylvania, during the Endnote Session at the Oncology Nurse Advisor Navigation Summit.
Precision medicine involves the identification of actionable mutations and agents that target those specific pathways. ONS member Debra Wujcik, PhD, RN, FAAN, the director of research at Carevive Systems, Inc., gave an overview of precision medicine therapies at the Oncology Nurse Advisor Navigation Summit.